A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma

Patients with advanced intrahepatic cholangiocarcinoma (ICC) have a poor prognosis and the therapeutic options available for treating ICC are limited. Sorafenib, a multikinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet derived growth factor receptor-β, B-Raf proto-onc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Ting-Ting, Wang, Wei, Jia, Wei-Dong, Xu, Ge-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431743/
https://www.ncbi.nlm.nih.gov/pubmed/28529557
http://dx.doi.org/10.3892/ol.2017.5847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431743/
https://www.ncbi.nlm.nih.gov/pubmed/28529557
http://dx.doi.org/10.3892/ol.2017.5847

Ejemplares similares